Jon C. Mills

Jon C. Mills

Auto-generated profile, based on publicly available information

Jon C. Mills


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in JAMA Psychiatry
Verified
Journal Article
Open access
PDF file
BPBrian W. Pence
Brian W. Pence
JMJon C. Mills
Jon C. Mills
ABAngela M. Bengtson
Angela M. Bengtson
BGBradley N. Gaynes
Bradley N. Gaynes
TBTiffany L. Breger
Tiffany L. Breger
MMMichael J. Mugavero
Michael J. Mugavero
Depression is one of the most common comorbidities affecting adults living with HIV, with prevalence estimates ranging from 20% to 40%.1-7 In addition to being a serious clinical concern, depression complicates the management of HIV: it has been linked to low adherence to antiretroviral therapy (ART),8 poor attendance at HIV primary care appointments,9 ART failure,10 accelerated clinical progression of HIV,11,12 and higher mortality rates.13-24

30 March 2018 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
JMJon C Mills
Jon C Mills
BPBrian W Pence
Brian W Pence
JTJonathan V Todd
Jonathan V Todd
ABAngela M Bengtson
Angela M Bengtson
TBTiffany L Breger
Tiffany L Breger
AAAdaora A Adimora
Adaora A Adimora
Research linking depression to mortality among people living with human immunodeficiency virus (PLWH) has largely focused on binary “always vs never” characterizations of depression. However, depression is chronic and is likely to have cumulative effects on mortality over time. Quantifying depression as a cumulative exposure may provide a better indication of the clinical benefit of enhanced depression treatment protocols delivered in HIV care settings. Women living with HIV (WLWH), naive to antiretroviral therapy, from the Women’s Interagency HIV Study were followed from their first visit in or after 1998 for up to 10 semiannual visits (5 years). Depressive symptoms were assessed using the Center for Epidemiologic Studies Depression (CES-D) scale. An area-under-the-curve approach was used to translate CES-D scores into a time-updated measure of cumulative days with depression (CDWD). We estimated the effect of CDWD on all-cause mortality using marginal structural Cox proportional hazards models. Overall, 818 women contributed 3292 woman-years over a median of 4.8 years of follow-up, during which the median (interquartile range) CDWD was 366 (97–853). Ninety-four women died during follow-up (2.9 deaths/100 woman-years). A dose–response relationship was observed between CDWD and mortality. Each additional 365 days spent with depression increased mortality risk by 72% (hazard ratio, 1.72; 95% confidence interval, 1.34–2.20). In this sample of WLWH, increased CDWD elevated mortality rates in a dose–response fashion. More frequent monitoring and enhanced depression treatment protocols designed to reduce CDWD may interrupt the accumulation of mortality risk among WLWH.

1 November 2019 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
JMJon C. PhD Mills
Jon C. PhD Mills
BPBrian W. Pence
Brian W. Pence
AEAndrew Edmonds
Andrew Edmonds
AAAdebola Adedimeji
Adebola Adedimeji
RSRebecca M. Schwartz
Rebecca M. Schwartz
AAAdaora A. Adimora
Adaora A. Adimora
Background: Data are limited on cumulative impacts of depression on engagement in care and HIV outcomes in women living with HIV (WLWH) during the era of universal antiretroviral therapy (ART). Understanding the relationship of accumulated depression with HIV disease management may help identify benefits of interventions to reduce severity and duration of depressive episodes. Setting: A cohort of WLWH (N = 1491) from the Women's Interagency HIV Study at 9 sites across the US. Methods: This longitudinal observational cohort study (2013–2017) followed WLWH for a maximum of 9 semiannual visits. Depression was quantified as a time-updated measure of percent of days depressed (PDD) created from repeated assessments using the Center for Epidemiologic Studies Depression scale. Marginal structural Poisson regression models were used to estimate the effects of PDD on the risks of missing an HIV care appointment, <95% ART adherence, and virological failure (≥200 copies/mL). Results: The risk of missing an HIV care appointment [risk ratio (RR) = 1.16, 95% confidence interval = 0.93 to 1.45; risk difference (RD) = 0.01, −0.01 to 0.03], being <95% ART adherent (RR = 1.27, 1.06–1.52; RD = 0.04, −0.01 to 0.07), and virological failure (RR = 1.09, 1.01–1.18; RD = 0.01, −0.01 to 0.03) increased monotonically with increasing PDD (comparing those with 25 to those with 0 PDD). The total effect of PDD on virological failure was fully (%100) mediated by being <95% ART adherent. Conclusions: Time spent depressed increases the risk of virological failure through ART adherence, even in the era of universal ART regimes forgiving of imperfect adherence.

5 January 2018 in BMC Family Practice
Verified
Journal Article
Open access
PDF file
LBLori A. Bilello
Lori A. Bilello
AHAllyson Hall
Allyson Hall
JHJeffrey Harman
Jeffrey Harman
CSChristopher Scuderi
Christopher Scuderi
NSNipa Shah
Nipa Shah
SSShenae Samuels
Shenae Samuels
Approximately 24 million Americans are living with diabetes. Patient activation among individuals with diabetes is critical to successful diabetes management. The Patient Centered Medical Home (PCMH) model holds promise for increasing patient activation in managing their health. However, what is not well understood is the extent to which individual components of the PCMH model, such as the quality of physician-patient interactions and organizational features of care, contribute to patient activation. This study’s objective is to determine the relative importance of the PCMH constructs or domains to patient activation among individuals living with diabetes. This study is a cross-sectional analysis of 1253 primary care patients surveyed with type II diabetes. The dependent variable, patient activation, was assessed using the Patient Activation Measure (PAM). Independent variables included 7 PCMH domains- organizational access, integration of care, comprehensive knowledge, office staff helpfulness, communication, interpersonal treatment and trust. Ordered logistic regression was performed to determine whether each PCMH domain was independently associated with patient activation, followed by a final ordered logistic regression that included all the PCMH domains in a single adjusted model. Using the full adjusted model, the odds of patients reporting higher activation scores (PAM) were found to be significant in the domains that represented organizational access (OR 1.56, 95% CI 1.31–1.85) and comprehensive knowledge (OR 1.44, 95% CI 1.13–1.85). Many practices have struggled with the challenge to develop fully functional patient-centered medical homes. In an effort to become more patient-centered, this study aimed to address what factors activated diabetic patients to adhere to diabetes management plan. Understanding these factors can help identify PCMH attributes that practices can prioritize and improve upon to assist their patients in improving health outcomes. Study was not a clinical trial; therefore it was not registered.

28 November 2017 in AIDS
Verified
Journal Article
Closed access
JMJon C. Mills
Jon C. Mills
JHJeffrey S. Harman
Jeffrey S. Harman
RCRobert L. Cook
Robert L. Cook
NMNicole M. Marlow
Nicole M. Marlow
CHChristopher A. Harle
Christopher A. Harle
BPBrian W. Pence
Brian W. Pence
Objective: Depression is highly prevalent among people living with HIV/AIDS (PLWHA) and has deleterious effects on HIV clinical outcomes. We examined changes in depression symptoms, viral suppression, and CD4+ T cells/μl among PLWHA diagnosed with depression who initiated antidepressant treatment during routine care, and compared the effectiveness of dual-action and single-action antidepressants for improving those outcomes. Design: Comparative effectiveness study of new user dual-action or single-action antidepressant treatment episodes occurring from 2004 to 2014 obtained from the Center for AIDS Research Network of Integrated Clinical Systems. Methods: We identified new user treatment episodes with no antidepressant use in the preceding 90 days. We completed intent-to-treat and per protocol evaluations for the main analysis. Primary outcomes, were viral suppression (HIV viral load <200 copies/ml) and CD4+ T cells/μl. In a secondary analysis, we used the Patient Health Questionnaire-9 (PHQ-9) to evaluate changes in depression symptoms and remission (PHQ <5). Generalized estimating equations with inverse probability of treatment weights were fitted to estimate treatment effects. Results: In weighted intent-to-treat analyses, the probability of viral suppression increased 16% after initiating antidepressants [95% confidence interval = (1.12, 1.20)]. We observed an increase of 39 CD4+T cells/μl after initiating antidepressants (30, 48). Both the frequency of remission from depression and PHQ-9 scores improved after antidepressant initiation. Comparative effectiveness estimates were null in all models. Conclusion: Initiating antidepressant treatment was associated with improvements in depression, viral suppression, and CD4+ T cells/μl, highlighting the health benefits of treating depression in PLWHA. Dual and single-action antidepressants had comparable effectiveness.

1 June 2017 in Journal of Affective Disorders
Verified
Journal Article
Closed access
JMJon C. Mills
Jon C. Mills
JHJeffrey S. Harman
Jeffrey S. Harman
RCRobert L. Cook
Robert L. Cook
NMNicole M. Marlow
Nicole M. Marlow
CHChristopher A. Harle
Christopher A. Harle
BPBrian W. Pence
Brian W. Pence